Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
2020; Springer Nature; Volume: 123; Issue: 5 Linguagem: Inglês
10.1038/s41416-020-0930-7
ISSN1532-1827
AutoresOliver Pickles, Lennard Y. W. Lee, Thomas Starkey, Luke Freeman-Mills, Anna Olsson‐Brown, Vinton W.T. Cheng, D.J. Hughes, Alvin Lee, Karin Purshouse, Gary Middleton,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoSummary The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.
Referência(s)